Beyond Air Stock Earnings Reports

Beyond Air reported strong commercial progress in FY2025 with revenue of $3.7M (220% growth YoY) driven entirely by U.S. hospital sales. Management reiterated near-term momentum, projecting at least $1.7M revenue for the quarter ending 06/30/2025 (>45% sequential growth) and provided FY2026 revenue guidance of $12M–$16M. The company submitted a PMA supplement for its next-generation LungFit PH2 (smaller, transportable, improved UI/backups) and expects PH2 to materially expand market share and hospital adoption once approved, though FDA timing is uncertain. International commercialization accelerated: CE Mark and multiple distribution agreements across more than two dozen countries (recent deals in India, Italy, Eastern Europe, Middle East), with initial international shipments already made and revenue expected to contribute in the back half of FY2026. Cost controls reduced operating expenses substantially (58% reduction over six quarters); R&D and SG&A declined vs. prior year, net loss narrowed to $46.6M, and net cash burn fell to $44.1M. Cash, equivalents, and marketable securities were $6.9M as of 03/31/2025 (plus post-period financing receipts), and management believes current financing suffices into calendar 2026 assuming revenue execution and continued cost control. Corporate/R&D highlights include a Vanderbilt luminary partnership for LungFit PH, a PMA supplement filing for PH2, Beyond Cancer’s pending phase 1b trial in Israel, and Neuronass receiving orphan drug designation for BA-102 and closing a $2M financing.